FI3768846T3 - Parantuneen tuoton omaavia viraalisia ja nonviraalisia nanoplasmidivektoreita - Google Patents

Parantuneen tuoton omaavia viraalisia ja nonviraalisia nanoplasmidivektoreita Download PDF

Info

Publication number
FI3768846T3
FI3768846T3 FIEP19715345.5T FI19715345T FI3768846T3 FI 3768846 T3 FI3768846 T3 FI 3768846T3 FI 19715345 T FI19715345 T FI 19715345T FI 3768846 T3 FI3768846 T3 FI 3768846T3
Authority
FI
Finland
Prior art keywords
replication
origin
sequence
seq
repeat sequence
Prior art date
Application number
FIEP19715345.5T
Other languages
English (en)
Finnish (fi)
Inventor
James A Williams
Original Assignee
Aldevron L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldevron L L C filed Critical Aldevron L L C
Application granted granted Critical
Publication of FI3768846T3 publication Critical patent/FI3768846T3/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051Methods of production or purification of viral material
    • C12N2740/15052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • C12N2750/14152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/101Plasmid DNA for bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/24Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/90Vectors containing a transposable element
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00Vectors comprising a special origin of replication system
    • C12N2820/55Vectors comprising a special origin of replication system from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185Escherichia
    • C12R2001/19Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
FIEP19715345.5T 2018-03-21 2019-03-20 Parantuneen tuoton omaavia viraalisia ja nonviraalisia nanoplasmidivektoreita FI3768846T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862645892P 2018-03-21 2018-03-21
PCT/US2019/023209 WO2019183248A1 (en) 2018-03-21 2019-03-20 Viral and non-viral nanoplasmid vectors with improved production

Publications (1)

Publication Number Publication Date
FI3768846T3 true FI3768846T3 (fi) 2023-06-30

Family

ID=66001381

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19715345.5T FI3768846T3 (fi) 2018-03-21 2019-03-20 Parantuneen tuoton omaavia viraalisia ja nonviraalisia nanoplasmidivektoreita

Country Status (13)

Country Link
US (1) US12600984B2 (https=)
EP (2) EP3768846B1 (https=)
JP (2) JP7520719B2 (https=)
KR (1) KR20210016330A (https=)
CN (2) CN112154208B (https=)
AU (2) AU2019240068B2 (https=)
CA (1) CA3093346A1 (https=)
DK (1) DK3768846T5 (https=)
ES (1) ES2950736T3 (https=)
FI (1) FI3768846T3 (https=)
LT (1) LT3768846T (https=)
SG (1) SG11202009009UA (https=)
WO (1) WO2019183248A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183248A1 (en) * 2018-03-21 2019-09-26 Nature Technology Corporation Viral and non-viral nanoplasmid vectors with improved production
US20220042038A1 (en) * 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
GB2700048B (en) 2019-09-18 2026-03-04 Aldevron Llc synthetic dna vectors and method of use
JP7833134B2 (ja) * 2020-03-11 2026-03-19 アルデブロン,エル.エル.シー. 細菌宿主株
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
CA3223292A1 (en) 2021-06-25 2022-12-29 Laura Van Lieshout Adeno-associated virus packaging systems
US20250114452A1 (en) 2021-08-04 2025-04-10 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
CN114045305B (zh) * 2021-10-15 2023-03-24 深圳市深研生物科技有限公司 多转座子系统
WO2023114901A2 (en) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
US20250354159A1 (en) * 2022-06-13 2025-11-20 Nanjing GenScript Biotech Co., Ltd. Wild-type-mutant pi protein switching expression system capable of increasing efficiency of preparing screening-tag-free plasmid
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性dnaベクター
CN117305339B (zh) * 2023-11-30 2024-02-06 苏州左旋星生物科技有限公司 优化大肠杆菌基因编辑的载体及其应用
WO2025160245A1 (en) 2024-01-25 2025-07-31 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
WO2025231315A2 (en) 2024-05-03 2025-11-06 Aldevron, L.L.C. Bacterial host strains
WO2026076187A1 (en) * 2024-10-03 2026-04-09 Aldevron, L.L.C. Compositions and methods for microbial production of antibiotic-free closed-ended linear dna

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04197185A (ja) * 1990-11-28 1992-07-16 Mitsui Toatsu Chem Inc 酵母発現ベクター及びこれを用いた誘導的発現
GB9506051D0 (en) * 1995-03-24 1995-05-10 Univ Singapore Gene expression
FR2738842B1 (fr) 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7279313B2 (en) 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US5922583A (en) 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
JP2004267001A (ja) * 2000-08-16 2004-09-30 Kansai Tlo Kk トランスジェニック哺乳動物及びその作製方法並びにこれを用いた遺伝子機能の解明方法
UY26317A1 (es) * 2000-08-30 2000-10-31 Alfonso Cayota Carlos Pritsch Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo
FR2821855B1 (fr) 2001-03-09 2004-04-02 Cayla Genes synthetiques et plasmides bacteriens depourvus de cpg
CA2794446C (en) * 2001-04-04 2015-09-08 Genencor International, Inc. Uncoupled productive and catabolic host cell pathways
US20060088837A1 (en) * 2002-04-26 2006-04-27 Kazunari Taira Expression system for stem-loop rna molecule having rnai effect
WO2005003359A1 (ja) * 2003-07-08 2005-01-13 Japan Science And Technology Corporation トランスジェニック生物を作製する方法およびシステム
GB0327056D0 (en) 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
MX2007001889A (es) 2004-08-19 2007-05-09 Nature Technology Corp Proceso para la fermentacion de adn de plasmido.
CA2577519A1 (en) * 2004-08-23 2006-03-30 Nucleonics, Inc. Multiple rna polymerase iii promoter expression constructs
TWI311152B (en) 2004-09-17 2009-06-21 Boehringer Ingelheim Rcv Gmbh & Co K Host-vector system for antibiotic-free cole1 plasmid propagation
US9018012B2 (en) 2005-01-20 2015-04-28 Nature Technology Corporation Vectors and methods for genetic immunization
EP1921140B1 (en) 2005-07-05 2011-12-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Mutant transposon vector and use thereof
US9017966B2 (en) 2007-05-23 2015-04-28 Nature Technology Corporation E. coli plasmid DNA production
EP2152889B1 (en) * 2007-05-29 2017-03-15 Nature Technology Corporation Vectors and methods for genetic immunization
ES2651911T3 (es) * 2007-08-14 2018-01-30 Commonwealth Scientific And Industrial Research Organisation Métodos mejorados de silenciamiento génico
US9045759B2 (en) 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
US9012226B2 (en) 2009-03-13 2015-04-21 Nature Technology Corporation Bacterial strains with improved plasmid stability
US9506082B2 (en) 2010-04-12 2016-11-29 Nature Technology Corporation Eukaryotic expression vectors resistant to transgene silencing
EP2788483B1 (en) * 2011-12-07 2018-06-27 Glenmark Pharmaceuticals S.A. Expression cassette
US9550998B2 (en) * 2012-08-29 2017-01-24 Nature Technology Corporation DNA plasmids with improved expression
US20150322439A1 (en) * 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
CA2914604A1 (en) * 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
WO2017025447A1 (en) 2015-08-10 2017-02-16 Curevac Ag Method of increasing the replication of a circular dna molecule
US11230720B2 (en) 2015-10-14 2022-01-25 Audentes Therapeutics, Inc. Nucleic acid molecules containing spacers and methods of use thereof
WO2019183248A1 (en) 2018-03-21 2019-09-26 Nature Technology Corporation Viral and non-viral nanoplasmid vectors with improved production
US20220042038A1 (en) * 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use

Also Published As

Publication number Publication date
DK3768846T5 (da) 2024-08-19
JP7520719B2 (ja) 2024-07-23
JP2021518150A (ja) 2021-08-02
US12600984B2 (en) 2026-04-14
EP4151735A1 (en) 2023-03-22
EP3768846B1 (en) 2023-06-21
DK3768846T3 (da) 2023-07-24
LT3768846T (lt) 2023-08-10
CA3093346A1 (en) 2019-09-29
JP2024138410A (ja) 2024-10-08
ES2950736T3 (es) 2023-10-13
AU2019240068B2 (en) 2025-03-13
SG11202009009UA (en) 2020-10-29
CN112154208B (zh) 2025-04-15
CN112154208A (zh) 2020-12-29
AU2019240068A1 (en) 2020-10-01
US20210010021A1 (en) 2021-01-14
AU2025203312A1 (en) 2025-05-29
WO2019183248A1 (en) 2019-09-26
KR20210016330A (ko) 2021-02-15
CN120249340A (zh) 2025-07-04
EP3768846A1 (en) 2021-01-27

Similar Documents

Publication Publication Date Title
FI3768846T3 (fi) Parantuneen tuoton omaavia viraalisia ja nonviraalisia nanoplasmidivektoreita
CN111492056B (zh) 用于细胞的遗传修饰的非整合型dna载体
JP2018534937A5 (https=)
JP6001702B2 (ja) ポリプリントラクト改変レトロウイルスベクター
KR102354365B1 (ko) 바이러스 벡터 생산 시스템
JP2019500030A5 (https=)
JP2021518150A5 (https=)
JP7759318B2 (ja) 産生系
CN102703424B (zh) 一种重组工程介导的大肠杆菌基因组点突变的方法
AU2021233908A1 (en) Bacterial host strains
KR20220139911A (ko) 렌티바이러스 벡터의 생산
WO2021181108A1 (en) Lentiviral vectors
JP2019503653A5 (https=)
Nicoud et al. Development of photoreceptor‐specific promoters and their utility to investigate EIAV lentiviral vector mediated gene transfer to photoreceptors
Camerini et al. A dormant internal ribosome entry site controls translation of feline immunodeficiency virus
WO2024061984A1 (en) Novel method
JP2007508842A (ja) 干渉rnaを運搬するためのレトロウイルスベクター
US11078495B2 (en) Methods and compositions for integration defective lentiviral vectors
US20200199619A1 (en) Lent-on-plus system for conditional expression in human stem cells
KR20250024602A (ko) 숙주 제한인자 녹아웃 세포주 및 이의 용도
WO2014196931A1 (en) A transposon for genome manipulation
RU2018147085A (ru) Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов ANG, ANGPT1, VEGFA, FGF1, HIF1α, HGF, SDF1, KLK4, PDGFC, PROK1, PROK2 для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-ANG или Escherichia coli SCS110-AF/VTvaf17-ANGPT1 или Escherichia coli SCS110-AF/VTvaf17-VEGFA или Escherichia coli SCS110-AF/VTvaf17-FGF1 или Escherichia coli SCS110-AF/VTvaf17-HIF1α или Escherichia coli SCS110-AF/VTvaf17-HGF или Escherichia coli SCS110-AF/VTvaf17-SDF1 или Escherichia coli SCS110-AF/VTvaf17-KLK4 или Escherichia coli SCS110-AF/VTvaf17-PDGFC или Escherichia coli SCS110-AF/VTvaf17- PROK1 или Escherichia coli SCS110-AF/VTvaf17- PROK2, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
KR20250024728A (ko) 2개의 플라스미드를 포함하는 신규한 포미바이러스 및 이의 용도
CN104711294A (zh) 一种基于禽网状内皮组织增生症病毒ltr的真核表达线性化载体的构建方法及应用
Guimarães ZNF675 evolutionary history and its novel role in neuronal regulatory networks